MedPath

European Organisation For Research & Treatment Of Cancer

🇬🇧United Kingdom
Ownership
Private
Employees
-
Market Cap
-
Website
http://www.eortc.be

Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer

Phase 2
Withdrawn
Conditions
Platinum-Sensitive Biliary Tract Cancer
Interventions
First Posted Date
2021-03-12
Last Posted Date
2022-06-01
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Registration Number
NCT04796454

PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)

Not Applicable
Recruiting
Conditions
Limited Stage Small Cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
Interventions
Radiation: Prophylactic cranial irradiation
First Posted Date
2021-03-10
Last Posted Date
2023-11-03
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
600
Registration Number
NCT04790253
Locations
🇦🇹

Medical University of Graz - Radio-oncology, Graz, Austria

🇧🇪

Institut Jules Bordet, Anderlecht, Belgium

🇧🇪

Universitair Ziekenhuis Antwerpen, Edegem, Belgium

and more 38 locations

A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma

Phase 3
Terminated
Conditions
Advanced Soft-tissue Sarcoma
Interventions
First Posted Date
2021-03-03
Last Posted Date
2024-02-22
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
14
Registration Number
NCT04780464
Locations
🇨🇾

Bank Of Cyprus Oncology Centre, Nicosia, Cyprus

🇯🇴

King Hussein Cancer Center, Amman, Jordan

Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

Not Applicable
Recruiting
Conditions
Gynecologic Cancer
Head and Neck Cancer
Renal Cancer
Bladder Cancer
Pancreatic Cancer
Skin Cancer
Sarcoma
Colon Cancer
Oligometastasis
Esophageal Cancer
Interventions
Radiation: Palliative RT
Radiation: Stereotactic body radiotherapy
First Posted Date
2020-08-04
Last Posted Date
2024-08-26
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
200
Registration Number
NCT04498767
Locations
🇧🇪

Institut Jules Bordet, Anderlecht, Belgium

🇧🇪

Universitair Ziekenhuis Gent, Gent, Belgium

🇧🇪

Gasthuiszusters Antwerpen - Sint-Augustinus, Wilrijk, Belgium

and more 10 locations

Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma

Phase 2
Active, not recruiting
Conditions
Medulloblastoma
Interventions
First Posted Date
2020-05-26
Last Posted Date
2024-08-26
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
20
Registration Number
NCT04402073
Locations
🇦🇺

Royal Adelaide Hospital, Adelaide, Australia

🇦🇺

Princess Alexandra Hospital - University Of Queensland, Brisbane, Australia

🇦🇺

Austin Health - Austin hospital, Melbourne, Australia

and more 47 locations

REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)

Phase 2
Terminated
Conditions
Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (Stage IA-IB)
Interventions
First Posted Date
2020-01-06
Last Posted Date
2023-11-09
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
2
Registration Number
NCT04218825
Locations
🇫🇷

CHU de Bordeaux - Groupe Hospitalier Saint-Andre - Hopital Saint-Andre, Bordeaux, France

🇫🇷

Assistance Publique Hopitaux Paris- APHP - APHP Nord - Univ De Paris Cite - Hop. Saint Louis, Paris, France

Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma

Phase 2
Recruiting
Conditions
Stage IB-IIB Cutaneous T-Cell Lymphoma
Interventions
Radiation: Total Skin Electron Beam Therapy (TSEB)
First Posted Date
2019-10-16
Last Posted Date
2024-04-05
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
43
Registration Number
NCT04128072
Locations
🇩🇰

University Hospitals Copenhagen - Rigshospitalet, Copenhagen, Denmark

🇫🇷

CHU de Bordeaux - Groupe Hospitalier Saint-Andre - Hopital Saint-Andre, Bordeaux, France

🇫🇷

Assistance Publique Hopitaux Paris- APHP Nord - Univ De Paris Cite - Hop. Saint Louis, Paris, France

and more 10 locations

Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

Phase 2
Active, not recruiting
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2019-10-15
Last Posted Date
2024-11-05
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
68
Registration Number
NCT04127110
Locations
🇧🇪

Institut Jules Bordet-Hopital Universitaire ULB, Brussels, Belgium

🇧🇪

Cliniques Universitaires Saint-Luc, Brussels, Belgium

🇧🇪

Universitair Ziekenhuis Antwerpen, Edegem, Belgium

and more 22 locations

Long-term Surival of GIST Patients ≥ 10 Years on Imatinib

Withdrawn
Conditions
GIST
Interventions
Other: No intervention
First Posted Date
2019-09-20
Last Posted Date
2020-09-02
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Registration Number
NCT04097093
© Copyright 2025. All Rights Reserved by MedPath